Clinical Trial: Leflunomide to Prevent Cytomegalovirus Reactivation in Stem Cell Transplant Patients

U.S., July 17 -- ClinicalTrials.gov registry received information related to the study (NCT07709013) titled 'Leflunomide to Prevent Cytomegalovirus Reactivation in Stem Cell Transplant Patients' on Jan. 25, 2025.

Brief Summary: Patients undergoing half-matched hematopoietic stem cell transplantation (HSCT) are at high risk of viral reactivation after bone marrow transplantation (BMT). The purpose of this study is to evaluate whether leflunomide can prevent cytomegalovirus (CMV) reactivation in these patients and to assess its safety.

The main questions it aims to answer are -

1. Does leflunomide prevent cytomegalovirus (CMV) related organ damage?

2. Does leflunomide prevent a rise in cytomegalovirus (CMV) copy number to more than 2000 c...